Sevasemten is an orally administered small molecule designed to prevent contraction-induced ... muscular dystrophy. The open-label, single-centre trial evaluated the drug's safety ...

an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA ...